Mohan Philip

Emergex Vaccines Holding Ltd. is a biotechnology company, which engages in the development of medicines against viral and bacterial infectious diseases. It focuses on the vaccines for dengue fever, Zika, Ebola, pandemic flu, and serious intra-cellular bacterial infections. The company was founded by Storme Moore-Thornicroft and Thomas Rademacher in 2016 and is headquartered in Abingdon, the United Kingdom.

Emergex Vaccines Holding Ltd. is a biotechnology company, which engages in the development of medicines against viral and bacterial infectious diseases. It focuses on the vaccines for dengue fever, Zika, Ebola, pandemic flu, and serious intra-cellular bacterial infections. The company was founded by Storme Moore-Thornicroft and Thomas Rademacher in 2016 and is headquartered in Abingdon, the United Kingdom.

Emergex Vaccines Holding Ltd. is a biotechnology company, which engages in the development of medicines against viral and bacterial infectious diseases. It focuses on the vaccines for dengue fever, Zika, Ebola, pandemic flu, and serious intra-cellular bacterial infections. The company was founded by Storme Moore-Thornicroft and Thomas Rademacher in 2016 and is headquartered in Abingdon, the United Kingdom.

ImmProNano, Inc. engages in cell based immunological assays, proteomic analysis and services, and nanotechnology applications and consultation solutions. The company was founded by Mohan Philip, Ramila Philip, Xiaofang Huang, and Aykan Karabudak and is headquartered in Doylestown, PA.

ImmProNano, Inc. engages in cell based immunological assays, proteomic analysis and services, and nanotechnology applications and consultation solutions. The company was founded by Mohan Philip, Ramila Philip, Xiaofang Huang, and Aykan Karabudak and is headquartered in Doylestown, PA.